<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Revive Therapeutics Expands into Phase III Clinical Trials
Image Overlay - Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics Expands into Phase III Clinical Trials

August 26, 2020

Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics will expand their candidate, Bucillamine, in patients with mild-moderate COVID-19 in phase III trials taking place in the Asia-Pacific Countries (“APAC”) and Canada. Revive expects to open the Phase 3 clinical trial for patient enrollment and dosing in September 2020. Yourway has a depot in Mississauga, Ontario in Canada, as well as in Beijing, China, Tokyo, Japan, Singapore, and Adelaide, Australia.

Back to Index
Media

Upcoming Events

Global Clinical Supplies Group (GCSG)

October 14-16, 2025
Hungary, Budapest

Clinical Outsourcing Group (COG)

October 21-22, 2025
Burlingame, California

Media

Articles

Case study: Coordinating a complex intercontinental shipment on a short timeline

Open chat
Come chat with us!
Hello! How can I help you?